Press Release: PTT Announces Departure of CEO Russ Yelton

For Immediate Release
Monday, October 23, 2017

Pinnacle Transplant Technologies Announces Departure of CEO Russ Yelton
Yelton to remain on the company’s board of advisors; bioscience industry executive Keith Stoneback named interim CEO.

Pinnacle Transplant Technologies, a leading manufacturer of bone and tissue allografts for human transplantation, announced today that Chief Executive Officer Russ Yelton will be leaving the company, effective October 23rd. He will remain on Pinnacle’s board of advisors. Medical device executive and current PTT board member Keith Stoneback will take over as CEO on an interim basis.

Russ Yelton PTTAlthough the numerous milestones reached with Pinnacle make his departure bittersweet, Yelton is excited to get back to supporting young startup businesses.

“I have greatly enjoyed working with Pinnacle over the past several years,” he said. “It is a truly special place with special people, and I know this important work will continue. I am looking forward to taking some time off before returning to work with startups which is my passion.”

Yelton began as an executive mentor for the company before being named CEO in April 2014. From that point, he helped spearhead Pinnacle’s maturation from a high-growth startup to an industry leader in regenerative medicine. Under his tenure, Pinnacle enjoyed 30% year-over-year revenue growth, accelerated its hiring to nearly 100 associates, and expanded the footprint of its Phoenix headquarters to nearly 40,000 square feet.

“I am truly grateful for Russ’ leadership over the last four years,” said PTT President and Executive Director Gabe Hyams. “His unwavering dedication to our mission has inspired new innovation in our product offerings, allowed us to develop a foundational culture for our associates and most importantly reached a point where we are are now improving the lives of more than 100,000 patients a year.”

PTT Chief Operating Officer Noah Stromer added: “We cannot thank Russ enough for his contributions during a critical period in our development. We would not be where we are without his commitment and his vision, and we wish him all the best going forward.”

Now the company turns to a new era of progress and innovation with Stoneback at the helm, who brings more than 30 years of executive-level leadership with medical device and health services businesses.

“We are excited for this next step in our own evolution as a company,” Hyams said. “We anticipate that the next several years will be marked by transformative growth as we continue to provide quality regenerative medical products to more and more patients all over the world.”

For more information, visit


About Pinnacle Transplant Technologies
Pinnacle Transplant Technologies is a regenerative medical company that manufactures innovative allografts to the highest standards of quality and safety for transplant into human recipients. To date, Pinnacle’s products have improved the lives of more than 100,000 individuals worldwide. Pinnacle operates out of a 24,000 square-foot facility located in Phoenix, Arizona, with a processing core that contains 10 validated cleanrooms and state-of-the-art equipment, such as CNC precision milling machines, designed to produce specialty allografts. For more information, visit

Media contacts

Greg Bullock,, 480.544.8320